Clinical Remission and Disease-Modifying Potential of Biologics in Severe Asthma Running Head: Clinical Remission and Disease-Modifying Potential in Severe Asthma

BACKGROUND: Biologics have shifted therapeutic ambition in severe asthma from disease control toward clinical remission. However, on-treatment remission remains a treatment state rather than proof of disease modification because residual biological, physiological, or structural abnormalities may persist and benefits observed during ongoing exposure cannot distinguish pharmacological suppression from durable change in disease course. SUMMARY: This review evaluates disease-modifying potential within a multidomain interpretive framework spanning clinical remission, biological change, physiological recovery, structural change, longitudinal trajectory, and durability as pharmacological exposure is reduced or withdrawn. Human mechanistic and clinical studies show that biologics can alter selected local-airway biological processes and, in some settings, physiological abnormalities, although responses across domains may dissociate. Structural effects are endpoint-dependent: mucus-plug burden is treatment responsive, and selected airway-wall remodeling features may change in defined cohorts, but universal or synchronous structural reversal has not been established. Earlier biologic initiation is associated with better subsequent outcomes, yet causal modification of long-term trajectory remains unproven. Withdrawal and dose-spacing studies show heterogeneous durability and variable pharmacological dependence, with both disease re-emergence and persistent benefit. KEY MESSAGES: Biologics can achieve profound disease suppression and selected disease-domain changes relevant to a disease-modifying interpretation. However, current evidence does not establish universal, durable disease modification or cure. Confidence in a disease-modifying interpretation would increase with convergent evidence of underlying-process change, altered longitudinal trajectory, and durability beyond continuous pharmacological exposure.

Authors

Publication Details

Journal
International Archives of Allergy and Immunology
Published
2026-11-18
DOI
https://doi.org/10.1159/iaa/adfag041
Primary Topic
Asthma and respiratory diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical Remission and Disease-Modifying Potential of Biologics in Severe Asthma Running Head: Clinical Remission and Disease-Modifying Potential in Severe Asthma

Jieying Zhong
1 links
International Archives of Allergy and Immunology
Asthma and respiratory diseases
article

Clinical Remission and Disease-Modifying Potential of Biologics in Severe Asthma Running Head: Clinical Remission and Disease-Modifying Potential in Severe Asthma

Jieying Zhong
article en

Abstract

BACKGROUND: Biologics have shifted therapeutic ambition in severe asthma from disease control toward clinical remission. However, on-treatment remission remains a treatment state rather than proof of disease modification because residual biological, physiological, or structural abnormalities may persist and benefits observed during ongoing exposure cannot distinguish pharmacological suppression from durable change in disease course. SUMMARY: This review evaluates disease-modifying potential within a multidomain interpretive framework spanning clinical remission, biological change, physiological recovery, structural change, longitudinal trajectory, and durability as pharmacological exposure is reduced or withdrawn. Human mechanistic and clinical studies show that biologics can alter selected local-airway biological processes and, in some settings, physiological abnormalities, although responses across domains may dissociate. Structural effects are endpoint-dependent: mucus-plug burden is treatment responsive, and selected airway-wall remodeling features may change in defined cohorts, but universal or synchronous structural reversal has not been established. Earlier biologic initiation is associated with better subsequent outcomes, yet causal modification of long-term trajectory remains unproven. Withdrawal and dose-spacing studies show heterogeneous durability and variable pharmacological dependence, with both disease re-emergence and persistent benefit. KEY MESSAGES: Biologics can achieve profound disease suppression and selected disease-domain changes relevant to a disease-modifying interpretation. However, current evidence does not establish universal, durable disease modification or cure. Confidence in a disease-modifying interpretation would increase with convergent evidence of underlying-process change, altered longitudinal trajectory, and durability beyond continuous pharmacological exposure.

International Archives of Allergy and Immunology
Good health and well-being
Asthma and respiratory diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon